Neuroscience Letters 591 (2015) Christian Moritz, Francesco Berardi, Carmen Abate and Francesca Peri View Paper Post navigationPreviousPrevious post:Anavex to Present at Sigma-1 Receptors SymposiumNextNext post:Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory BoardRelated PostsAnavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study UpdatesDecember 16, 2019Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019December 10, 2019Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 ConferenceDecember 4, 2019Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study UpdatesDecember 16, 2019
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019December 10, 2019
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer’s Disease (CTAD) 2019 ConferenceDecember 4, 2019
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019
